Core Insights - Maxus Mining Inc. has confirmed widespread high-grade polymetallic mineralization across the Alturas East Project, indicating significant exploration potential in the Slocan Mining Division of British Columbia [1][3][4] Exploration Highlights - The 2025 exploration program revealed a 500-meter mineralized veining corridor along the Gold Quartz Ridge, with notable assay results including 18.20 g/t gold, 131.00 g/t silver, and 0.23% copper [4][15] - Multiple stratigraphic horizons and vein systems were identified, showcasing a robust, multi-phase mineralizing system comparable to historic producers in the region [4][11] - Outcrop sampling indicated strong multi-commodity potential with elevated values of gold, silver, nickel, lead, titanium, and zinc across various target areas [4][11] Specific Target Areas - **Olympus East**: Strong silver-lead-zinc values were confirmed, with sample G018669 returning 9.40 g/t Ag, 0.26% Pb, and 0.99% Zn, indicating a proximal mineral source [11][14] - **Olympus West**: Elevated nickel-silver-zinc values were noted, with sample G018671 showing 2050 ppm Ni, suggesting multiple mineralizing events [12][14] - **Gold Quartz Ridge**: This area returned some of the strongest polymetallic values, with historic waste pile samples yielding results such as 18.20 g/t Au and 131 g/t Ag, indicating significant mineralization potential [15][16] Geological Context - The Alturas East Block is strategically located near the past-producing Highland Surprise Mine, characterized by polymetallic veins containing gold, silver, lead, zinc, and copper [5][6] - The property has not undergone systematic modern exploration since the 1970s, presenting significant exploration upside [6][10] Company Overview - Maxus Mining Inc. is focused on locating and advancing economic mineral properties in premier jurisdictions, with a diversified portfolio totaling approximately 15,098 hectares across British Columbia [25][26]

Core Viewpoint - Neuphoria Therapeutics Inc. is addressing what it perceives as a deceptive campaign by Lynx1 Master Fund LP aimed at distracting shareholders from Lynx1's own shortcomings and lack of a clear plan [1][2][3] Company Positioning - Neuphoria emphasizes its commitment to transparency and value creation, urging stockholders to support its nominees while withholding votes for Lynx1's nominees [2][8] - The company is focused on developing therapies for neuropsychiatric disorders, with its lead drug candidate BNC210 targeting PTSD [9] Response to Lynx1's Claims - Neuphoria refutes Lynx1's assertions, presenting a detailed counterargument to each claim made by Lynx1, highlighting the company's strategic actions and board qualifications [4][5][6][7] - The company asserts that Lynx1's nominees lack the necessary experience and understanding of the company's needs, particularly in neuropsychiatric disorders [5][7] Strategic Review and Clinical Trials - Following the AFFIRM-1 Phase 3 clinical trial results, which missed primary and secondary endpoints, Neuphoria has halted development of BNC210 for social anxiety disorder and is conducting a strategic review [9] - The company is also engaged in partnerships, including one with Merck, to advance its pipeline for treating cognitive deficits in Alzheimer's disease [9] Board Composition and Governance - Neuphoria defends its current board's qualifications and experience, contrasting them with Lynx1's nominees, who are portrayed as lacking relevant expertise [6][7] - The company emphasizes the importance of having a strong cash balance and strategic oversight in navigating its clinical trials and corporate governance [6][7]

Core Viewpoint - Enerflex Ltd. announced a private offering of $400 million in senior notes due 2031 to redeem its outstanding 9.000% Senior Secured Notes due 2027, contingent upon the completion of the offering [1][2]. Offering Details - The offering consists of $400 million in aggregate principal amount of senior notes due 2031 [1]. - The net proceeds from the offering, along with borrowings from the secured revolving credit facility, will be used to fully redeem the 2027 Notes [2]. - The redemption of the 2027 Notes is set for December 11, 2025, at a price of 102.25% of the principal amount plus accrued interest [2]. Regulatory Compliance - The notes will be offered in a private offering relying on exemptions from registration requirements under the Securities Act of 1933 and applicable Canadian securities laws [3][4]. - The offering is limited to qualified institutional buyers and non-U.S. persons outside the United States [3]. Forward-Looking Information - The news release contains forward-looking information regarding market conditions and the completion of the offering [6][7]. - Management's expectations are based on various assumptions, including the supportiveness of market conditions for the offering [8].

CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Peer To Peer Network (OTC: PTOP) today issued a summary of its November 27th investor call, where newly appointed division president Derek McCarthy outlined the Company’s AI-driven strategy for transforming investor communications and engagement. The Company opened the call by expressing its deep appreciation for the over two dozen shareholders who took time out of their schedules on the night before Thanksgiving to join the discussion. Overview of PTOP I ...

Core Insights - Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company focused on developing therapeutic proteins and antibodies targeting G-protein coupled receptors (GPCRs) [4] Upcoming Conferences - Tectonic management will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 3:30 PM EST in New York, NY, in a fireside chat format [2] - The company will also attend the Evercore 8th Annual Healthcare Conference on December 3, 2025, in Miami, FL, conducting investor meetings [2][3] Company Overview - Tectonic utilizes its proprietary GEODe™ technology platform to enhance GPCR-targeted drug discovery, aiming to develop biologic medicines for areas with significant unmet medical needs [4] - The company is headquartered in Watertown, Massachusetts, and focuses on improving patient quality of life through innovative therapeutic options [4]

Premieres to Over 125 Million Pay Cable Subscribers and Free Streaming Viewers Via Envoy TV and Envoy FAST Channels, Dr. Phil Combined Social Following Tops 27 Million Network Debuts With More Than 200 Podcasts and 15,000 Hours of Premium Library Content Drawn From the Combined Catalogs of PodcastOne and Envoy Media Co. LOS ANGELES, Dec. 01, 2025 (GLOBE NEWSWIRE) -- LiveOne (NASDAQ: LVO) announced today that its subsidiary PodcastOne (NASDAQ: PODC) and Dr. Phil’s Envoy Media Co. have partnered to launch a c ...

Core Viewpoint - Ascentage Pharma Group International is set to provide an update on its innovative portfolio and pipeline during an investor webcast, focusing on key presentations at the upcoming 67th American Society of Hematology Annual Meeting [1]. Company Overview - Ascentage Pharma is a global, commercial stage, integrated biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapies for unmet medical needs in cancer [4]. - The company has developed a rich pipeline of innovative drug products, including inhibitors targeting key apoptotic pathway proteins and next-generation kinase inhibitors [4]. Product Pipeline - The first approved product, Olverembatinib, is a third-generation BCR-ABL1 inhibitor for treating chronic myeloid leukemia (CML) with specific mutations and is included in the China National Reimbursement Drug List [5]. - The company is conducting a global registrational Phase III trial (POLARIS-2) for Olverembatinib in CML and additional trials for newly diagnosed Ph+ acute lymphoblastic leukemia (ALL) and SDH-deficient gastrointestinal stromal tumors (GIST) [5]. - The second approved product, Lisaftoclax, is a Bcl-2 inhibitor for various hematologic malignancies and is undergoing multiple global registrational Phase III trials [6]. Research and Development - Ascentage Pharma has established a portfolio of global intellectual property rights and formed partnerships with leading biotechnology and pharmaceutical companies, including Takeda, AstraZeneca, Merck, and Pfizer [7].

AI study to begin with Kitimat Copper-Gold Project; Copper Quest completes initial site visit and work programVANCOUVER, British Columbia, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Copper Quest Exploration Inc. (CSE: CQX; OTCQB: IMIMF; FRA: 3MX) (“Copper Quest” or the “Company”) is pleased to announce it has entered into a strategic partnership with U.S. based Exploration Technologies Inc. (“ExploreTech”) to deploy generative artificial intelligence across its project portfolio, beginning with the Kitimat Copper-Go ...

Ground-Based Gravity Survey Launching in December to Follow Up on Historic Uranium Intercepts First Defined by Cameco and Denison MinesVANCOUVER, British Columbia, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Foremost Clean Energy Ltd. (NASDAQ: FMST) (CSE: FAT) (“Foremost” or the “Company"), Foremost Clean Energy Ltd. (NASDAQ: FMST) is pleased to announce that the Saskatchewan Ministry of Environment has issued a three-year exploration permit for the Company’s Turkey Lake Uranium Project (“Turkey Lake”), located on th ...

– SGT-212 has been granted FDA Rare Pediatric Disease and Fast Track designations – – SGT-212 is the only dual route gene therapy in development to treat Friedreich’s ataxia – – FALCON Phase 1b clinical trial participant screening underway – CHARLESTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it received Rare Pediatric ...